enavatuzumab

01/01/2017 - "These preclinical studies demonstrate that enavatuzumab can exert its potent antitumor activity by actively recruiting and activating myeloid effectors to kill tumor cells. "
01/01/2017 - "Consistent with the xenograft studies, human effector cells preferentially migrated toward in vivo-responsive tumor cells treated by enavatuzumab in vitro, with the majority of migratory cells being monocytes. "
01/01/2017 - "The initial evidence for a role of effector cells was obtained in a subset of tumor xenograft mouse models whose response to enavatuzumab relied on the binding of Fc of the antibody to Fcγ receptor. "
01/01/2014 - "PDL192 also significantly delayed tumor relapse after CR. "
01/01/2014 - "Using both responding and resistant PDX tumors after PDL192 administration, RT-QPCR were performed on a wide list of selected candidate genes to identify predictive markers of response. "

02/01/2013 - "These data provide the rationale to evaluate enavatuzumab as a potential therapy for the treatment of breast cancer."
01/01/2014 - "Predictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenografts."
02/01/2013 - "To determine the functional relevance of TweakR, breast cancer cell lines were treated in vitro and in vivo with enavatuzumab, a humanized mAb against TweakR. "
02/01/2013 - "Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb."
02/01/2013 - "Enavatuzumab inhibited the in vitro growth of TweakR-expressing breast cancer cell lines, and this activity was augmented by cross-linking the mAb. In addition, enavatuzumab significantly inhibited the in vivo growth of multiple breast cancer xenograft models including a model of metastasis. "

02/01/2013 - "Enavatuzumab inhibited the in vitro growth of TweakR-expressing breast cancer cell lines, and this activity was augmented by cross-linking the mAb. In addition, enavatuzumab significantly inhibited the in vivo growth of multiple breast cancer xenograft models including a model of metastasis. "
02/01/2013 - "TweakR is highly expressed in all subtypes of invasive ductal breast cancer, and enavatuzumab administration exhibited a dose-dependent inhibition of primary tumor growth and lung metastasis and enhanced the antitumor activity of several chemotherapy agents currently used to treat breast cancer. "